Related Experiment Video
Updated: Aug 16, 2025
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
Validation of Rates of Mean Deviation Change as Clinically Relevant End Points for Glaucoma Progression
Felipe A Medeiros1, Alessandro A Jammal2
1Vision, Imaging and Performance Laboratory, Duke Eye Center, Duke University, Durham, North Carolina; Department of Electrical and Computer Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University School Medicine, Durham, North Carolina.
Purpose:
To investigate whether rates of standard automated perimetry (SAP) mean deviation (MD) over an initial 2-year follow-up period were predictive of events of visual field progression over an extended follow-up.
Design:
Longitudinal, prospective, observational study.
Participants:
Two hundred forty-six eyes of 168 patients with glaucoma followed up every 6 months for up to 5 years.
Methods:
Patients were required to have a minimum of 5 reliable SAP tests during the first 2 years of follow-up. Events of progression were evaluated using 2 methods: Guided Progression Analysis (GPA; Carl Zeiss Meditec, Inc) and a United States Food and Drug Administration (FDA)-suggested end point. The date of the first test showing progression after the first 2 years was considered to be the event date. Rates of change in SAP MD were calculated for the first 2 years of follow-up, and joint longitudinal survival models were used to assess the risk of faster initial MD loss for subsequent progression based on each event analysis.
Main Outcome Measure:
Risk of having an event of progression based on initial rates of SAP MD change.
Results:
Fifty-six eye (22.8%) showed an event of progression by the GPA and 51 eyes (20.7%) did so by the FDA end point. Each 0.1-dB/year faster rate of SAP MD loss in the first 2 years was associated with a 26% increase in risk of a GPA progression end point developing (R2 = 76%) and 32% risk of an FDA-based end point developing (R2 = 83%). A reduction of 30% in the rate of MD change in the first 2 years was associated with a 20% reduction in the cumulative probability of a progression event developing over 5 years of follow-up.
Conclusions:
Rates of SAP MD change for eyes with glaucoma calculated over the initial 2 years of follow-up were strongly predictive of events of progression over subsequent follow-up. Our findings give support for the use of slopes of MD change as suitable end points of progression in clinical trials.
Financial Disclosure(S):
Proprietary or commercial disclosure may be found after the references.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:52Regression Toward the Mean
01:25Glaucoma: Overview
01:28Angle Closure Glaucoma: Treatment
01:19Testing a Claim about Standard Deviation
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
01:13Mean Absolute Deviation
Let us consider a dataset containing the number of unsold cupcakes in five shops: 10, 15, 8, 7, and 10. Initially, calculate the sample mean. Then calculate the deviation, or the difference, between each data value and the mean. Next, the absolute values of these deviations are added and divided by the sample size to...